Physician profile
Daniel W Dick
NPI 1629224100
$2,138.42
in general payments reported to CMS, 2019-2025
21 companies · $824 in 2025
The $824 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.59 · 2020: $80.54 · 2021: $24.00 · 2022: $292 · 2023: $390 · 2024: $430 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.67 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $321.41 | 2022-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $225.47 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $192.35 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $175.82 | 2021-2025 | Aplenzin |
| Lundbeck LLC | $142.59 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $124.36 | 2023-2025 | Qelbree, Qelbree |
| Neuronetics, INC. | $122.35 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $118.99 | 2025 | Cobenfy |
| Corium, LLC | $116.46 | 2023-2024 | Azstarys, Azstarys |
| Alkermes, INC. | $102.08 | 2023-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $99.34 | 2019-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $81.60 | 2019-2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $62.29 | 2019-2024 | Austedo Xr |
| Tris Pharma INC | $55.99 | 2020 | |
| Axsome Therapeutics, INC. | $54.72 | 2024 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $52.58 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $29.81 | 2024 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.03 | 2025 | Caplyta |
| Noven Therapeutics, LLC | $16.01 | 2024 | Xelstrym |
| Tms Neurohealth Centers INC. | $13.27 | 2025 | Tms Neurohealth Centers INC. |
| Allergan, INC. | $12.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.